CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer

Wei, XX; Cai, JQ; Zhuang, J; Zheng, B; Sui, YX; Zhang, GF; Lin, Y; Sun, H

Sun, H (corresponding author), Fujian Med Univ, Fujian Prov Hosp, Shengli Clin Med Coll, Dept Pharm, Fuzhou 350000, Peoples R China.

PHARMACOGENOMICS, 2020; 21 (1): 43

Abstract

Aim: To assess the cost-effectiveness of CYP2D6*10 genetic testing for the management of Chinese women with hormone receptor-positive (HR+) breast can......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索